InvestorsHub Logo
Followers 8
Posts 1912
Boards Moderated 0
Alias Born 09/10/2012

Re: None

Tuesday, 06/28/2022 3:35:45 AM

Tuesday, June 28, 2022 3:35:45 AM

Post# of 392
ESSA PHARMA INC
EPI-7386 WAS SAFE AND WELL-TOLERATED AT ALL DOSE LEVELS
EPI-7386 SCHEDULES TESTED WITH PLASMA TARGET CONCENTRATIONS ACHIEVED AND CLINICALLY IMPORTANT EFFICACY SIGNALS
ESSA PHARMA INC - EXPECTS TO INITIATE PHASE 1B MONOTHERAPY EXPANSION STUDY IN Q3 2022

We are pleased with the progress in advancing our novel prostate cancer candidate EPI-7386 as a monotherapy in patients with advanced mCRPC.

We continue to be excited by our combination trials evaluating EPI-7386 with the four leading, commercially available antiandrogens in earlier line patient populations

I hope some huge portfolios get excited too...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EPIX News